{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:00:57Z","timestamp":1789664457662,"version":"4.0.1"},"reference-count":17,"publisher":"Federa\u00e7\u00e3o das Associa\u00e7\u00f5es de Ginecologia e Obstetr\u00edcia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,4]]},"DOI":"10.61622\/rbgo\/2024rbgo79","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:43:46Z","timestamp":1733942626000},"source":"Crossref","is-referenced-by-count":6,"title":["Zuranolone for postpartum depression: a systematic review and meta-analysis of two randomized studies"],"prefix":"10.61622","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4704-2318","authenticated-orcid":false,"given":"Juliana Almeida","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2329-8575","authenticated-orcid":false,"given":"Karine","family":"Eskandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-4867","authenticated-orcid":false,"given":"Marcos Aur\u00e9lio Ara\u00fajo","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4375-9522","authenticated-orcid":false,"given":"Chris Elizabeth","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"47794","reference":[{"issue":"1","key":"key20241211130108_B1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-clinpsy-050212-185612","article-title":"Postpartum depression: current status and future directions","volume":"9","author":"O\u2019Hara","year":"2013","unstructured":"1 O\u2019Hara MW, McCabe JE. Postpartum depression: current status and future directions. Annu Rev Clin Psychol. 2013;9(1):379-407. doi: 10.1146\/annurev-clinpsy-050212-185612","journal-title":"Annu Rev Clin Psychol"},{"issue":"3","key":"key20241211130108_B2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4103\/0019-5545.117131","article-title":"Diagnostic and statistical manual of mental disorders 5: a quick glance","volume":"55","author":"Vahia","year":"2013","unstructured":"2 Vahia V. Diagnostic and statistical manual of mental disorders 5: a quick glance. Indian J Psychiatry. 2013;55(3):220-3. doi: 10.4103\/0019-5545.117131","journal-title":"Indian J Psychiatry"},{"issue":"2","key":"key20241211130108_B3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.curtheres.2005.04.006","article-title":"Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey","volume":"66","author":"Ashton","year":"2005","unstructured":"3 Ashton AK, Jamerson BD, L Weinstein W, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp. 2005;66(2):96-106. doi: 10.1016\/j.curtheres.2005.04.006","journal-title":"Curr Ther Res Clin Exp"},{"issue":"9","key":"key20241211130108_B4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial","volume":"78","author":"Deligiannidis","year":"2021","unstructured":"4 Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, et al. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry. 2021;78(9):951-9. doi: 10.1001\/jamapsychiatry.2021.1559","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"key20241211130108_B5","article-title":"A comprehensive review on postpartum depression","volume":"14","author":"Suryawanshi","year":"2022","unstructured":"5 Suryawanshi O, Pajai S. A comprehensive review on postpartum depression. Cureus. 2022;14(12):e32745. doi: 10.7759\/cureus.32745","journal-title":"Cureus"},{"key":"key20241211130108_B6","volume-title":"Zuranolone for the treatment of postpartum depression","author":"The American College of Obstetricians and Gynecologists","year":"2023","unstructured":"6 The American College of Obstetricians and Gynecologists. Zuranolone for the treatment of postpartum depression. 2023 [cited 2023 Nov 20]. Available from: https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2023\/08\/zuranolone-for-the-treatment-of-postpartum-depression"},{"issue":"1","key":"key20241211130108_B7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41398-023-02514-2","article-title":"Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder","volume":"13","author":"Cutler","year":"2023","unstructured":"7 Cutler AJ, Mattingly GW, Maletic V. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Transl Psychiatry. 2023;13(1):228. doi: 10.1038\/s41398-023-02514-2","journal-title":"Transl Psychiatry"},{"issue":"1","key":"key20241211130108_B8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","unstructured":"8 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi: 10.1136\/jnnp.23.1.56","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"key20241211130108_B9","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","unstructured":"9 Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37.","journal-title":"Psychiatry (Edgmont)"},{"issue":"9","key":"key20241211130108_B10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","article-title":"Zuranolone for the treatment of postpartum depression","volume":"180","author":"Deligiannidis","year":"2023","unstructured":"10 Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, et al. Zuranolone for the treatment of postpartum depression. Am J Psychiatry. 2023;180(9):668-75. doi: 10.1176\/appi.ajp.20220785","journal-title":"Am J Psychiatry"},{"key":"key20241211130108_B11","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3389\/fphar.2018.01127","article-title":"Neurosteroids in pain management: a new perspective on an old player","volume":"9","author":"Joksimovic","year":"2018","unstructured":"11 Joksimovic SL, Covey DF, Jevtovic-Todorovic V, Todorovic SM. Neurosteroids in pain management: a new perspective on an old player. Front Pharmacol. 2018;9:1127. doi: 10.3389\/fphar.2018.01127","journal-title":"Front Pharmacol"},{"key":"key20241211130108_B12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.12688\/f1000research.18758.1","article-title":"Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience","volume":"8","author":"L\u00fcscher","year":"2019","unstructured":"12 L\u00fcscher B, M\u00f6hler H. Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience. F1000Res. 2019;8:751. doi: 10.12688\/f1000research.18758.1","journal-title":"F1000Res"},{"key":"key20241211130108_B13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neuroscience.2011.04.010","article-title":"Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis","volume":"191","author":"Luchetti","year":"2011","unstructured":"13 Luchetti S, Huitinga I, Swaab DF. Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis. Neuroscience. 2011;191:6-21. doi: 10.1016\/j.neuroscience.2011.04.010","journal-title":"Neuroscience"},{"key":"key20241211130108_B14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jad.2013.09.019","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): a systematic review of randomized clinical trials","volume":"152-154","author":"De Crescenzo","year":"2014","unstructured":"14 De Crescenzo F, Perelli F, Armando M, Vicari S. Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): a systematic review of randomized clinical trials. J Affect Disord. 2014;152-154:39-44. doi: 10.1016\/j.jad.2013.09.019","journal-title":"J Affect Disord"},{"key":"key20241211130108_B15","volume-title":"Monitoramento do horizonte tecnol\u00f3gico: medicamentos para o tratamento do transtorno depressivo maior","author":"Melo","year":"2022","unstructured":"15 Melo DO, Ribeiro TB, Biase TM. Monitoramento do horizonte tecnol\u00f3gico: medicamentos para o tratamento do transtorno depressivo maior. Bras\u00edlia (DF): CONITEC; 2022 [cited 2024 Jun 28]. Available from: https:\/\/www.gov.br\/conitec\/pt-br\/midias\/radar\/2022\/informemht_transtorno-depressivo-maior_publicado.pdf"},{"issue":"2","key":"key20241211130108_B16","doi-asserted-by":"crossref","first-page":"22m14445","DOI":"10.4088\/JCP.22m14445","article-title":"Zuranolone in major depressive disorder: results from MOUNTAIN\u2014A Phase 3, multicenter, double-blind, randomized, placebo-controlled trial","volume":"84","author":"Clayton","year":"2023","unstructured":"16 Clayton AH, Lasser R, Nandy I, Sankoh AJ, Jonas J, Kanes SJ. Zuranolone in major depressive disorder: results from MOUNTAIN\u2014A Phase 3, multicenter, double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2023;84(2):22m14445. doi: 10.4088\/JCP.22m14445","journal-title":"J Clin Psychiatry"},{"key":"key20241211130108_B17","doi-asserted-by":"crossref","first-page":"102308","DOI":"10.1016\/j.eclinm.2023.102308","article-title":"Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses","volume":"66","author":"Lin","year":"2023","unstructured":"17 Lin YW, Tu YK, Hung KC, Liang CS, Tseng PT, Lin PY, et al. Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses. EClinicalMedicine. 2023;66:102308. doi: 10.1016\/j.eclinm.2023.102308","journal-title":"EClinicalMedicine"}],"container-title":["Revista Brasileira de Ginecologia e Obstetr\u00edcia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:43:53Z","timestamp":1733942633000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalrbgo.org\/article\/zuranolone-for-postpartum-depression-a-systematic-review-and-meta-analysis-of-two-randomized-studies\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":17,"alternative-id":["10.61622\/rbgo\/2024rbgo79"],"URL":"https:\/\/doi.org\/10.61622\/rbgo\/2024rbgo79","relation":{},"ISSN":["0100-7203","1806-9339"],"issn-type":[{"value":"0100-7203","type":"print"},{"value":"1806-9339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e-rbgo79"}}